

**Supplement Table 1. Baseline characteristics of two different types of therapeutic strategies for LAGC.**

Characteristics		NAT-Surgery n=494 (%)	Surgery-ACT n=2285 (%)	<i>P</i>
<b>Age</b>	mean ( $\pm$ SD)	55.58( $\pm$ 10.62)	56.21( $\pm$ 10.30)	0.152
<b>Gender</b>	Female	132 (26.7)	559(24.5)	0.293
	Male	362 (73.3)	1726(75.5)	
<b>Tumor location</b>	Upper stomach	129 (26.1)	862(37.7)	<0.001
	Lower stomach	221 (44.7)	1361(59.6)	
	Whole stomach	144 (29.1)	62(2.7)	
<b>Grade</b>	Well differentiated	9 (1.8)	57(2.5)	<0.001
	Moderately differentiated	95 (19.2)	941(41.2)	
	Poor differentiated	390 (78.9)	1287(56.3)	
<b>Clinical T Stage*</b>	T2	17 (3.4)	205(9.0)	<0.001
	T3	151 (30.6)	1017(44.5)	
	T4a	326 (66.0)	1063(46.5)	
<b>Clinical N Stage*</b>	cN0	37 (7.5)	350(15.3)	<0.001
	cN-positive	457 (92.5)	1935(84.7)	
<b>Clinical TNM Stage*</b>	II	61 (12.3)	676(29.6)	<0.001
	III	433 (87.7)	1609(70.4)	
<b>NAT Strategies</b>	nCRT	100 (20.2)	-	
	nCT	394 (79.8)	-	

\* Tumor stage according to the American Joint Committee on Cancer, 8th Edition.

NAT, neoadjuvant treatment; ACT, adjuvant chemotherapy; SD, standard deviation.